Clinical TrialHighlighted
MHID-50217702022European Journal of Inflammation
Aleksandra Milovancev, Jovana Avakumovic, Patrik Drid, Nikola Todorovic, Valdemar Stajer, Sergej M Ostojic
Molecular hydrogen (H2) has been recently put forward as a possible adjunct therapeutics in COVID-19 due to its anti-inflammatory and pulmo-protective effects.1,2 An open-label randomized trial in 44 patients with laboratory-confirmed COVID-19 from seven hospitals in China demonstrated that 3-day hydrogen inhalation resulted in significantly more patients with improved disease severity and reduced dy
Observational StudyHighlighted
MHID-5864798PMID: 347652122021Clinical Case Reports
Ram B. Singh, Ghazi Halabi, Ghizal Fatima, Richa H. Rai, Alexander T. Tarnava, Tyler W. LeBaron
Administration of molecular hydrogen dissolved in water to patient with COVID-19-like symptoms may improve oxygen levels and exercise capacity.
Clinical TrialHighlighted
MHID-0587967PMID: 319380042019Biology of Sport
Dejan Javorac, Valdemar Stajer, Laszlo Ratgeber, Jozsef Betlehem, Sergej Ostojic
In this randomized, double-blind, placebo-controlled, crossover pilot trial, we evaluated the effects of 7-day H2 inhalation on exercise performance outcomes and serum hormonal and inflammation profiles in a cohort of young men and women. All participants (age 22.9 ± 1.5 years; body mass index 23.4 ± 2.5 kg m-2; 10 women and 10 men) were allocated to receive either gaseous hydrogen (4%) or placebo
